NR4A1 and breast carcinoma: For instance, the final scope of a health technology appraisal for abemaciclib (TA810), recently published by the National Institute for Health and Care Excellence, describes the target population as “adults with hormone receptor‐positive, HER2‐negative, node‐positive early breast cancer after definitive surgery of the primary breast tumor at high‐risk of recurrence.”37